The results published in 2010 reported that the use of TA according to the protocol resulted in a decline in overall mortality and in the hemorrhage-associated mortality, with values of 14.5 % vs. 16 %, p = 0.0035 and OR = 0.91 CI 95% 0.85; 0.97, and 4.9% vs. 5.7%, p = 0.077 with a RR = 0.85 CI 95%; 0.76; 0.96, respectively, with no statistically significant differences reported in terms of adverse events when administered during the first 8 h of the injury.
16%, para una p = 0,0035 y un OR de 0,91 IC95%: 0,85-0,97, y del 4,9% vs. 5,7%, para una p = 0,077 y un RR de 0,85 IC 95% entre 0,76-0,96, respectivamente, sin que se reportasen diferencias estadísticas en los eventos adversos cuando fue administrado durante las primeras 8 h de la lesión.